During the past decade, Takatsuki Red Cross Hospital conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 8 clinical trials were completed, i.e. on average, 53.3% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 8 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Takatsuki Red Cross Hospital" #1 sponsor was "Eli Lilly and Company" with 8 trials, followed by "Bayer" with 5 trials sponsored, "AstraZeneca" with 1 trials sponsored, "Celgene" with 1 trials sponsored and "Japan Multinational Trial Organization" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Takatsuki Red Cross Hospital" #1 collaborator was "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator, "Ministry of Health, Labour and Welfare, Japan" with 1 trials as a collaborator and "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Takatsuki Red Cross Hospital" are "Heart Failure" (3 trials), "Type 2 Diabetes" (3 trials), "Type 2 Diabetes Mellitus" (3 trials), "Asthma" (1 trials) and "Chronic Heart Failure With Preserved Ejection Fraction" (1 trials). Many other conditions were trialed in "Takatsuki Red Cross Hospital" in a lesser frequency.

Most popular intervention types in "Takatsuki Red Cross Hospital" are "Drug" (15 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Tirzepatide" (6 trials), "Dulaglutide" (2 trials), "Insulin Degludec" (2 trials) and "Insulin Efsitora Alfa" (2 trials). Other intervention names were less common.

The vast majority of trials in "Takatsuki Red Cross Hospital" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Takatsuki Red Cross Hospital". undefined are not yet recruiting, undefined are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Takatsuki Red Cross Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Takatsuki Red Cross Hospital, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".